Angela Vitrano

Improving survival with deferiprone treatment in patients with thalassemia major: A prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies

Aurelio Maggio, Angela Vitrano, Marcello Capra et al. · Blood Cells Molecules and Diseases · 2009 · 96 citations

Hematology, Clinical Trials, Italian Society +5

Long‐term sequential deferiprone–deferoxamine <i>versus</i> deferiprone alone for thalassaemia major patients: a randomized clinical trial

Aurelio Maggio, Angela Vitrano, Marcello Capra et al. · British Journal of Haematology · 2009 · 69 citations

Drug Safety, Therapeutic Drug Monitoring, Randomized Clinical Trial +11

Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial

Aurelio Maggio, Antonis Kattamis, Mariagrazia Felisi et al. · The Lancet Haematology · 2020 · 68 citations

Drug Safety, Transfusion-dependent Haemoglobinopathies, Pediatric Hematology +8

The era of comparable life expectancy between thalassaemia major and intermedia: Is it time to revisit the major‐intermedia dichotomy?

Angela Vitrano, Giuseppina Calvaruso, Eliana Lai et al. · British Journal of Haematology · 2016 · 56 citations · Full text

Heart Failure, Iron Metabolism, Prognosis +19

Survival and causes of death in 2,033 patients with non-transfusion-dependent β-thalassemia

Khaled M. Musallam, Angela Vitrano, Antonella Meloni et al. · Haematologica · 2021 · 45 citations · Full text

Transfusion Medicine, Hematology, Blood Transplantation +3